glp 1 neuroinflammation Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Repurposing glucagon-like peptide-1 receptor agonists

Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most

Published April 3, 2020

The target dose per injection is protocol-dependent

In a study using cultured rat hippocampal neurons, pre-treatment of nerve cells with GLP-1 resulted in a weakened Ca 2+ response to glutamate and weakened membrane depolarization (46)

10.1016/j.urology.2005.08.010 Urology